多西他赛联合卡培他滨方案在新辅助化疗三阴乳腺癌与非三阴乳腺癌中的近期疗效观察  

Short-term Curative Effects of Docetaxel Combined with Capecitabine in Neoadjuvant Chemotherapy of Triplenegative Breast Cancer and Non Triple-negative Brest Cancer

作　　者：张淼[1] 宋敏[2] 屈淑贤[2] 章国晶[2] 郭放[2] 韩雅玲[3] 谢晓冬[2] 

机构地区：[1]大连医科大学研究生院,辽宁大连116044 [2]沈阳军区总医院肿瘤科,沈阳110840 [3]沈阳军区总医院心血管病研究所,沈阳110840

出　　处：《解放军医药杂志》2015年第3期55-57,62,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：国家十二五重大新药创制平台子课题(2012ZX09303016-002);2012年辽宁省科技攻关计划课题(2012225019)

摘　　要：目的探讨三阴乳腺癌(triple-negative breast cancer,TNBC)与非三阴乳腺癌患者应用多西他赛联合卡培他滨(DX)方案行新辅助化疗的临床疗效及不良反应。方法选择2008年7月—2013年8月收治的102例乳腺癌患者,其中TNBC 27例,非TNBC75例,均应用DX方案新辅助化疗。观察临床疗效和毒副反应发生情况。结果TNBC患者总有效率与非TNBC患者比较差异无统计学意义(P>0.05)。TNBC患者病理完全缓解率、临床完全缓解率高于非TNBC患者(P<0.01,P<0.05)。毒副反应主要表现为胃肠道反应、骨髓抑制及手足综合征等,TNBC与非TNBC患者毒副反应发生率比较差异无统计学意义(P>0.05)。结论 TNBC患者较非TNBC患者对DX方案新辅助化疗更敏感,且未增加毒副反应发生率。Objective To compare the curative effect and adverse reactions of Docetaxel combined with Capecitabine（ DX） in neoadjuvant chemotherapy of patients with triple-negative breast cancer（ TNBC） or non triple-negative breast cancer. Methods A total of 102 patients with breast cancer during July 2008 and August 2013 underwent DX neoadjuvant chemotherapy,including 27 patients and 75 non-TNBC patients. The curative effect and adverse reactions were observed. Results There was no significant difference in the overall response（ OR） between TNBC patients and non- TNBC patients（ P〈0. 05）. The pathological complete response and clinical complete remission rates of TNBC patients were significantly higher than those of non-TNBC patients（ P〈0. 01,P 0. 05）. The main adverse and toxic reactions were gastrointestinal tract indisposition,bone marrow suppression,hand-foot syndrome,etc. There was no significant difference in incidence rates of adverse and toxic reactions between TNBC patients and non- TNBC patients（ P〈0. 05）. Conclusion The neoadjuvant chemotherapy using Docetaxel combined with Capecitabine shows a higher sensitivity in TNBC patients,compared with that in non- TNBC patients without an increase of incidence rate of adverse reactions.

关 键 词：多西他赛 卡培他滨 三阴乳腺癌 新辅助化疗 

分 类 号：R739.9[医药卫生—肿瘤]